Infections & Infestations

Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

Infections & Infestations Resource Center

Welcome to the MPR Infections & Infestations Resource Center, where you will find everything you need to make informed clinical decisions.

Drug Monographs

Click on the subcategory below to find drug monographs for that particular area.

News

Isentress Receives New Labeling Update

Merck announced that the FDA has approved a labeling update for Isentress (raltegravir) tablets to include 156-week data from the STARTMRK study.

'Pedicure Fish' May Harbor Pathogens for Zoonotic Disease

Garra rufa (G. rufa), or doctor fish - widely used in the health and beauty industries around the world, although currently banned in many US states - may harbor zoonotic disease pathogens.

BioThrax Administration Schedule Changed

The FDA has approved a change to the administration schedule of BioThrax (anthrax vaccine adsorbed) to a three-dose primary series of IM injections at 0, 1, and 6 months.

SAFETY ALERT: Risk of Cardiovascular Death with Zithromax

The FDA is notifying healthcare professionals of a new study reporting a small increase in cardiovascular death, and in the risk of death from any cause, in patients treated with a 5-day course of azithromycin (Zithromax; Pfizer) compared to persons treated with amoxicillin, ciprofloxacin, or no drug.

Azithromycin Tied to Increased Risk of Cardiovascular Mortality

Azithromycin treatment is associated with an increased risk of cardiovascular and all-cause mortality.

COMPLERA

9/22/2011

Gilead Sciences, Inc.

Pharmacological Class: Nucleoside analogue reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor.

Active Ingredient(s): Emtricitabine 200mg, tenofovir disoproxil fumarate 300mg, rilpivirine 25mg; tabs.

Indication: HIV-1 infection.

EDURANT

9/1/2011

Janssen Therapeutics

Pharmacological Class: Non-nucleoside reverse transcriptase inhibitor (NNRTI)

Active Ingredient(s): Rilpivirine 25mg; tablets.

Indication: HIV-1 infection in antiretroviral treatment-naïve adult patients, in combination with other antiretroviral agents.

INCIVEK

7/14/2011

Vertex Pharmaceuticals

Pharmacological Class: Hepatitis C virus NS3/4A protease inhibitor.

Active Ingredient(s): Telaprevir 375mg; tablets.

Indication: Chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin in patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based therapy, including prior null responders, and relapsers. Not for use as monotherapy.